Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma

[1]  A. Ejaz,et al.  Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials , 2020, Journal of clinical medicine.

[2]  T. Pawlik,et al.  Association of Perioperative Transfusion with Recurrence and Survival After Resection of Distal Cholangiocarcinoma: A 10-Institution Study from the US Extrahepatic Biliary Malignancy Consortium , 2019, Annals of Surgical Oncology.

[3]  G. Honda,et al.  Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). , 2019, Japanese journal of clinical oncology.

[4]  M. Katz,et al.  Perioperative Therapy for Borderline Resectable Pancreatic Cancer: What and When? , 2019, Annals of Surgical Oncology.

[5]  Matthias Eikermann,et al.  Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer , 2018, Annals of Surgical Oncology.

[6]  G. Honda,et al.  A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study , 2018, Journal of Gastroenterology.

[7]  Jeffrey E. Lee,et al.  Risk‐stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy , 2018, Surgery.

[8]  J. Lacy,et al.  Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. , 2018, Journal of the National Cancer Institute.

[9]  Jeffrey E. Lee,et al.  Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma , 2017, JAMA surgery.

[10]  D. Gouma,et al.  The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After , 2017, Surgery.

[11]  Boris Sepesi,et al.  Lack of Association Between Dexamethasone and Long-Term Survival After Non-Small Cell Lung Cancer Surgery. , 2016, Journal of cardiothoracic and vascular anesthesia.

[12]  J. Vauthey,et al.  Positive Impact of Epidural Analgesia on Oncologic Outcomes in Patients Undergoing Resection of Colorectal Liver Metastases , 2016, Annals of Surgical Oncology.

[13]  M. Katz,et al.  Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma. , 2015, Hematology/oncology clinics of North America.

[14]  Jeffrey E. Lee,et al.  Active Surveillance for Adverse Events Within 90 Days: The Standard for Reporting Surgical Outcomes After Pancreatectomy , 2015, Annals of Surgical Oncology.

[15]  B. Chortkoff,et al.  Factors Associated with Improved Survival after Resection of Pancreatic Adenocarcinoma: A Multivariable Model , 2015, Anesthesiology.

[16]  D. Sessler,et al.  Is Dexamethasone Associated with Recurrence of Ovarian Cancer? , 2014, Anesthesia and analgesia.

[17]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[18]  M. Katz,et al.  Management of borderline resectable pancreatic cancer. , 2014, Seminars in radiation oncology.

[19]  S. Bergese,et al.  Consensus Guidelines for the Management of Postoperative Nausea and Vomiting , 2014, Anesthesia and analgesia.

[20]  A. Hartle,et al.  Routine use of dexamethasone for postoperative nausea and vomiting: the case against , 2013, Anaesthesia.

[21]  M. Katz,et al.  Treatment of Borderline Resectable Pancreatic Cancer , 2013, Current Treatment Options in Oncology.

[22]  K. Lassen,et al.  Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. , 2012, Clinical nutrition.

[23]  D. Flum,et al.  Importance of Perioperative Glycemic Control in General Surgery: A Report From the Surgical Care and Outcomes Assessment Program , 2012, Annals of surgery.

[24]  W. Hawkins,et al.  The Accordion Severity Grading System of Surgical Complications , 2009, Annals of surgery.

[25]  D. Gouma,et al.  Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). , 2007, Surgery.

[26]  I. Saiki,et al.  Increased surgical stress promotes tumor metastasis. , 2003, Surgery.

[27]  M. Blajchman.  Immunomodulation and Blood Transfusion , 2002, American journal of therapeutics.

[28]  J. Masferrer,et al.  Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. , 2002, Cancer research.

[29]  Jeffrey E. Lee,et al.  Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival , 2013, Journal of Gastrointestinal Surgery.

[30]  K. Lassen,et al.  Guidelines for Perioperative Care for Pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society Recommendations , 2012, World Journal of Surgery.